Billets de Michelle Dawson

Billet publié sur Twitter/X le 16/12/2013 21:23

Twitter/X Publication avec DOI crossref Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Publication avec DOI Récupéré Publication crossref

Nouchine Hadjikhani, Nicole R Zürcher, Ophelie Rogier, Torsten Ruest, Loyse Hippolyte, Yehezkel Ben-Ari, Eric Lemonnier (2015). Improving emotional face perception in autism with diuretic bumetanide: A proof-of-concept behavioral and functional brain imaging pilot study. Autism, 19(2), 149-157. SAGE Publications.

Publication date
16/12/2013
Identifiant
10.1177/1362361313514141
Auteurs
Nouchine Hadjikhani, Nicole R Zürcher, Ophelie Rogier, Torsten Ruest, Loyse Hippolyte, Yehezkel Ben-Ari, Eric Lemonnier
Source
Autism
Détails
19(2), 149-157
Type de référence
article
Éditeur
SAGE Publications
Source de métadonnées
crossref

Résumé

Clinical observations have shown that GABA-acting benzodiazepines exert paradoxical excitatory effects in autism, suggesting elevated intracellular chloride (Cl–) i and excitatory action of GABA. In a previous double-blind randomized study, we have shown that the diuretic NKCC1 chloride importer antagonist bumetanide, that decreases (Cl–) i and reinforces GABAergic inhibition, reduces the severity of autism symptoms. Here, we report results from an open-label trial pilot study in which we used functional magnetic resonance imaging and neuropsychological testing to determine the effects of 10 months bumetanide treatment in adolescents and young adults with autism. We show that bumetanide treatment improves emotion recognition and enhances the activation of brain regions involved in social and emotional perception during the perception of emotional faces. The improvement of emotion processing by bumetanide reinforces the usefulness of bumetanide as a promising treatment to improve social interactions in autism.

Auteur·ices de l’étude dans cette référence citée